Hyphens Pharma International Limited (SGX:1J5)

Singapore flag Singapore · Delayed Price · Currency is SGD
0.350
-0.005 (-1.41%)
At close: Apr 27, 2026
20.69%
Market Cap 108.10M
Revenue (ttm) 177.37M
Net Income (ttm) 5.84M
Shares Out 308.87M
EPS (ttm) 0.02
PE Ratio 18.82
Forward PE 8.75
Dividend 0.02 (4.23%)
Ex-Dividend Date May 6, 2026
Volume 101,000
Average Volume 134,090
Open 0.355
Previous Close 0.355
Day's Range 0.350 - 0.355
52-Week Range 0.275 - 0.395
Beta 0.16
RSI 62.76
Earnings Date May 12, 2026

About SGXC:1J5

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Pharmaceutical and Medical Aesthetics; Proprietary Brands; and Digital Platform and E-Pharmacy segments. The Pharmaceutical and Medical Aesthetics segment markets and sells a range of pharmaceutical and medical aesthetics products, including the Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Pia... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 474
Stock Exchange Singapore Exchange - Catalist
Ticker Symbol 1J5
Full Company Profile

Financial Performance

In 2025, SGXC:1J5's revenue was 177.37 million, a decrease of -9.24% compared to the previous year's 195.42 million. Earnings were 5.84 million, a decrease of -42.67%.

Financial Statements

News

There is no news available yet.